Global Von Willebrand Disease Treatment Market 2019-2023

フォン・ウィルブランド病治療の世界市場2019-2023

◆タイトル:Global Von Willebrand Disease Treatment Market 2019-2023
◆商品コード:IRTNTR30291
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月22日
◆ページ数:115
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、フォン・ウィルブランド病治療の世界市場について調査・分析し、市場概要、市場環境、フォン・ウィルブランド病治療市場規模、製品別(デスモプレシン、補充療法、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・フォン・ウィルブランド病治療の世界市場概要
・フォン・ウィルブランド病治療の世界市場環境
・フォン・ウィルブランド病治療の世界市場動向
・フォン・ウィルブランド病治療の世界市場規模
・フォン・ウィルブランド病治療の世界市場:業界構造分析
・フォン・ウィルブランド病治療の世界市場:製品別(デスモプレシン、補充療法、その他)
・フォン・ウィルブランド病治療の世界市場:地域別市場規模・分析
・フォン・ウィルブランド病治療の北米市場規模・予測
・フォン・ウィルブランド病治療のヨーロッパ・中東・アフリカ市場規模・予測
・フォン・ウィルブランド病治療のアジア太平洋市場規模・予測
・フォン・ウィルブランド病治療の主要国分析
・フォン・ウィルブランド病治療の世界市場:意思決定フレームワーク
・フォン・ウィルブランド病治療の世界市場:成長要因、課題
・フォン・ウィルブランド病治療の世界市場:競争環境
・フォン・ウィルブランド病治療の世界市場:関連企業情報(ベンダー分析)

138 pages, November 2018
About this market
The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients’ perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually. Technavio’s analysts have predicted that the von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.
Market Overview
Rising number of assistance programs for patients
The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.
Cost intensive treatment
High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.
For the detailed list of factors that will drive and challenge the growth of the von Willebrand disease treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Desmopressin – Market size and forecast 2018-2023
• Replacement therapy – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter
• CSL
• Grifols
• Octapharma
• Shire
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global rare disease drugs market
Exhibit 02: Segments of global rare disease drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Inheritance of VWD
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Desmopressin – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Desmopressin – Year-over-year growth 2019-2023 (%)
Exhibit 22: Replacement therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Replacement therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Reimbursement programs in North America for hemophilia and its related diseases
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Patient assistance programs
Exhibit 43: Special drug designations
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Baxter – Vendor overview
Exhibit 51: Baxter – Business segments
Exhibit 52: Baxter – Organizational developments
Exhibit 53: Baxter – Geographic focus
Exhibit 54: Baxter – Segment focus
Exhibit 55: Baxter – Key offerings
Exhibit 56: Baxter – Key customers
Exhibit 57: CSL – Vendor overview
Exhibit 58: CSL – Business segments
Exhibit 59: CSL – Organizational developments
Exhibit 60: CSL – Geographic focus
Exhibit 61: CSL – Segment focus
Exhibit 62: CSL – Key offerings
Exhibit 63: CSL – Key customers
Exhibit 64: Grifols – Vendor overview
Exhibit 65: Grifols – Business segments
Exhibit 66: Grifols – Organizational developments
Exhibit 67: Grifols – Geographic focus
Exhibit 68: Grifols – Segment focus
Exhibit 69: Grifols – Key offerings
Exhibit 70: Grifols – Key customers
Exhibit 71: Octapharma – Vendor overview
Exhibit 72: Octapharma – Organizational developments
Exhibit 73: Octapharma – Key offerings
Exhibit 74: Octapharma – Key customers
Exhibit 75: Shire – Vendor overview
Exhibit 76: Shire – Business segments
Exhibit 77: Shire – Organizational developments
Exhibit 78: Shire – Geographic focus
Exhibit 79: Shire – Key offerings
Exhibit 80: Shire – Key customers



【掲載企業】

Baxter、CSL、Grifols、Octapharma、Shire

★調査レポート[フォン・ウィルブランド病治療の世界市場2019-2023] (Global Von Willebrand Disease Treatment Market 2019-2023 / IRTNTR30291)販売に関する免責事項
[フォン・ウィルブランド病治療の世界市場2019-2023] (Global Von Willebrand Disease Treatment Market 2019-2023 / IRTNTR30291)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆